Elotuzumab is an IgG1 mAb that targets signaling lymphocytic activation molecule F7 (SLAMF7), also known as CD319, which is highly expressed on MM, NK and other immune cells (132). Here, SLAMF7 is linked to Miyoshi myopathy.